CIK 0000818033 · Accelerated filer
HERON THERAPEUTICS, INC. /DE/
Sign in to watch- Ticker
- HRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 942875566
- Phone
- 8582514400
- Business address
- 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- AP PHARMA INC /DE/, ADVANCED POLYMER SYSTEMS INC /DE/
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-10-13 | Quart Barry D Chief Executive Officer | Grant or award · Restricted Stock Units | +195,417 | 195,417 | ||
| 2021-10-13 | POYHONEN JOHN President & CCO | Option exercise | +1,250 | 23,452 | ||
| 2021-10-13 | POYHONEN JOHN President & CCO | Shares withheld for taxes | −433 | $10.55 | $5K | 23,019 |
| 2021-10-13 | POYHONEN JOHN President & CCO | Option exercise · Restricted Stock Units | −1,250 | 15,000 | ||
| 2021-10-13 | POYHONEN JOHN President & CCO | Grant or award · Employee Stock Option (Right to Buy) | +92,200 | 92,200 | ||
| 2021-10-13 | POYHONEN JOHN President & CCO | Grant or award · Restricted Stock Units | +55,320 | 55,320 | ||
| 2021-10-13 | Peraza Lisa VP, Chief Accounting Officer | Option exercise | +552 | 14,388 | ||
| 2021-10-13 | Peraza Lisa VP, Chief Accounting Officer | Shares withheld for taxes | −191 | $10.55 | $2K | 14,197 |
| 2021-10-13 | Peraza Lisa VP, Chief Accounting Officer | Option exercise · Restricted Stock Units | −552 | 6,625 | ||
| 2021-10-13 | Peraza Lisa VP, Chief Accounting Officer | Grant or award · Employee Stock Option (Right to Buy) | +13,013 | 13,013 | ||
| 2021-10-13 | Peraza Lisa VP, Chief Accounting Officer | Grant or award · Restricted Stock Units | +23,424 | 23,424 | ||
| 2021-10-13 | MANHARD KIMBERLY EVP, Drug Development | Option exercise | +1,250 | 3,701 | ||
| 2021-10-13 | MANHARD KIMBERLY EVP, Drug Development | Shares withheld for taxes | −433 | $10.55 | $5K | 3,268 |
| 2021-10-13 | MANHARD KIMBERLY EVP, Drug Development | Option exercise · Restricted Stock Units | −1,250 | 15,000 | ||
| 2021-10-13 | MANHARD KIMBERLY EVP, Drug Development | Grant or award · Employee Stock Option (Right to Buy) | +92,200 | 92,200 | ||
| 2021-10-13 | MANHARD KIMBERLY EVP, Drug Development | Grant or award · Restricted Stock Units | +55,320 | 55,320 | ||
| 2021-09-21 | Christian Waage Director | Sale | −300 | $12.31 | $4K | 3,500 |
| 2021-09-21 | Johnson Craig A Director | Sale | −250 | $12.30 | $3K | 3,090 |
| 2021-07-13 | Szekeres David Leslie EVP, Chief Operating Officer | Option exercise | +1,250 | 3,597 | ||
| 2021-07-13 | Szekeres David Leslie EVP, Chief Operating Officer | Shares withheld for taxes | −433 | $13.48 | $6K | 3,164 |
Page 25 of 28 · 557 trades